PeptideStack
5.2kquestions
20kanswers
220users

Is FLOW a fair comparison of liraglutide against its comparator arm?

Asked 2 Dec 2025Modified 8 months agoViewed 15k times
24

Conditions: FLOW · liraglutide.

I want to know whether there is evidence behind this or only repetition.

I have checked the obvious registries and monographs without success.

Has anyone verified this independently?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questionssemaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
shareeditfollowflag
DC
askedDr_Idris_Coulibaly40k1382 Dec 2025
3I tested this on two lots and got the same answer, so at least it reproduces. – forty_two_c 8 months ago
2The timing signature is the useful part. Everything else is confounded. – tandem_gradient 6 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 15k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.